Trial Profile
Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2018
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Merck Serono
- 16 Aug 2018 New trial record